Business Description
Entero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05502L1052
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.49 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.33 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 87.9 | |||||
3-Year EPS without NRI Growth Rate | 74.9 | |||||
3-Year FCF Growth Rate | 84.9 | |||||
Future 3-5Y EPS without NRI Growth Rate | 60.63 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.21 | |||||
Quick Ratio | 1.21 | |||||
Cash Ratio | 0.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1182.5 | |||||
Shareholder Yield % | -1163.05 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -34.84 | |||||
ROA % | -27.05 | |||||
ROIC % | -32.81 | |||||
ROC (Joel Greenblatt) % | -8811.87 | |||||
ROCE % | -108.9 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.06 | |||||
EV-to-EBIT | -3.19 | |||||
EV-to-EBITDA | -3.19 | |||||
EV-to-Forward-Revenue | -64.47 | |||||
EV-to-FCF | -5.02 | |||||
Earnings Yield (Greenblatt) % | -31.35 | |||||
FCF Yield % | -897.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Entero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -45.613 | ||
Beta | 0 | ||
Volatility % | 46.99 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 78.96 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 78.96 - 78.96 | ||
Shares Outstanding (Mil) | 2.75 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Entero Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Entero Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Entero Therapeutics Inc Frequently Asked Questions
What is Entero Therapeutics Inc(FRA:366)'s stock price today?
When is next earnings date of Entero Therapeutics Inc(FRA:366)?
Does Entero Therapeutics Inc(FRA:366) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |